Targeting the NLRP3 Inflammasome with Colchicine in COVID-19: Therapeutic Evidence and Future Implications for Influenza

Vanyo Mitev

Open source

DOI
10.3390/ijms27156827
Published
2026-07-30
Container
International Journal of Molecular Sciences
Publisher
MDPI AG
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/ijms27156827,
  title = {Targeting the NLRP3 Inflammasome with Colchicine in COVID-19: Therapeutic Evidence and Future Implications for Influenza},
  author = {Vanyo Mitev},
  year = {2026},
  journal = {International Journal of Molecular Sciences},
  doi = {10.3390/ijms27156827},
  url = {https://doi.org/10.3390/ijms27156827}
}

RIS

TY  - JOUR
TI  - Targeting the NLRP3 Inflammasome with Colchicine in COVID-19: Therapeutic Evidence and Future Implications for Influenza
AU  - Vanyo Mitev
PY  - 2026
JO  - International Journal of Molecular Sciences
DO  - 10.3390/ijms27156827
UR  - https://doi.org/10.3390/ijms27156827
ER  - 

APA

Mitev, V. (2026). Targeting the NLRP3 Inflammasome with Colchicine in COVID-19: Therapeutic Evidence and Future Implications for Influenza. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27156827

Source records